[18F] JNJ 70099731
Alternative Names: [18F]-JNJ-70099731Latest Information Update: 16 Jun 2021
At a glance
- Originator Janssen Research & Development
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 03 Jun 2021 Preclinical trials in Unspecified (Diagnosis) in USA (IV)
- 03 Jun 2021 Janssen Research & Development plans a phase I brain kinetic trial (In volunteers, Diagnosis) in Belgium (IV) in June 2021 (NCT04911543)